News Headlines Article

Onyx, UCSF deal targets cancer-fighting projects
San Francisco Business Times

Onyx Pharmaceuticals Inc. is throwing open its net to UCSF cancer projects, hoping to pick and choose from a haul that could include preclinical and clinical cancer drug-development programs as well as new ways of designing drug trials. Financial terms of the three-year deal weren’t disclosed, but Dr. Pablo Cagnoni, Onyx’s executive vice president of global research and development and technical operations, said the projects would focus on blood cancers, solid tumors and potential cancer biomarkers.